TrialImmunotherapy2024

Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II).

Stanley Szefler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.